TSE:MBX Microbix Biosystems - MBX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Microbix Biosystems Inc. Please log in to your account or sign up in order to add this asset to your watchlist. C$0.36 -0.01 (-2.70%) (As of 03/24/2023 05:20 PM ET) Add Compare Share Share Today's RangeC$0.36▼C$0.3650-Day RangeC$0.30▼C$0.4052-Week RangeC$0.30▼C$0.69Volume5,500 shsAverage Volume52,617 shsMarket CapitalizationC$49.84 millionP/E Ratio34.00Dividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesHeadlinesSocial Media About Microbix Biosystems (TSE:MBX) StockMicrobix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. It manufactures a range of critical biological materials for the diagnostics industry, notably test ingredients for immunoassays and quality assessment and proficiency testing controls (QAPs) that support sample collection devices. The company also applies its biological expertise and infrastructure to develop other proprietary products, primarily viral transport medium (DxTM) to test for pathogens and Kinlytic Urokinase, a biologic thrombolytic drug used to treat blood clots. Microbix Biosystems Inc. was founded in 1988 and is based in Mississauga, Canada.Read More Receive MBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Microbix Biosystems and its competitors with MarketBeat's FREE daily newsletter. Email Address MBX Stock News HeadlinesMarch 20, 2023 | finance.yahoo.comGovernments of Ontario and Canada Invest in MicrobixMarch 1, 2023 | finance.yahoo.comMicrobix Supporting Australian Point-of-Care Testing ProgramMarch 24, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …February 11, 2023 | finance.yahoo.comMicrobix Biosystems First Quarter 2023 Earnings: Revenues Miss ExpectationsFebruary 9, 2023 | finanznachrichten.deMicrobix Biosystems Inc.: Microbix Reports Results for Q1 Fiscal 2023 Sales of $2.5 million, Net Loss of $1.3 millionFebruary 9, 2023 | finance.yahoo.comMicrobix Reports Results for Q1 Fiscal 2023 Sales of $2.5 million, Net Loss of $1.3 millionFebruary 9, 2023 | finance.yahoo.comMicrobix Reports Results for Q1 Fiscal 2023 Sales of $2.5 million, Net Loss of $1.3 millionFebruary 6, 2023 | finance.yahoo.comMicrobix Presenting Results of Collaboration with Health PEIMarch 24, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …January 30, 2023 | finance.yahoo.comMicrobix Launches QAP to Support “Monkeypox” TestingDecember 27, 2022 | finance.yahoo.comAnalysts Just Slashed Their Microbix Biosystems Inc. (TSE:MBX) EPS NumbersDecember 23, 2022 | finance.yahoo.comMicrobix Biosystems Inc. (TSE:MBX) Not Lagging Market On Growth Or PricingDecember 22, 2022 | finance.yahoo.comMicrobix Reports Record Sales for Fiscal 2022October 6, 2022 | finance.yahoo.comMicrobix Presenting Test-Workflow Validation Results at EMMDOctober 6, 2022 | finance.yahoo.comIs Microbix Biosystems Inc.'s (TSE:MBX) Latest Stock Performance Being Led By Its Strong Fundamentals?September 28, 2022 | finance.yahoo.comMicrobix Announces Initiation of Normal Course Issuer BidSeptember 20, 2022 | reuters.comMicrobix Biosystems IncAugust 11, 2022 | finance.yahoo.comMicrobix Reports Results for Q3 Fiscal 2022August 10, 2022 | finance.yahoo.comMicrobix Executes Substantial QAPs Supply AgreementAugust 5, 2022 | finance.yahoo.comInvestors in Microbix Biosystems (TSE:MBX) have made a splendid return of 104% over the past three yearsMay 31, 2022 | finance.yahoo.comIs Microbix Biosystems (TSE:MBX) Using Too Much Debt?May 12, 2022 | finance.yahoo.comMicrobix Reports Record Results for Q2 Fiscal 2022April 29, 2022 | finance.yahoo.comMicrobix Biosystems Inc. (TSE:MBX) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?April 28, 2022 | finance.yahoo.comMicrobix Presenting at the 2022 Bloom Burton ConferenceApril 19, 2022 | finance.yahoo.comMicrobix Presenting Respiratory Virus Controls Data at Two EventsApril 8, 2022 | finance.yahoo.comMicrobix Presenting HPV Product Results at EUROGINMarch 29, 2022 | finance.yahoo.comMicrobix Invests to Further Scale Its BusinessSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Microbix Biosystems and its competitors with MarketBeat's FREE daily newsletter. Email Address MBX Company Calendar Last Earnings2/09/2023Today3/24/2023Next Earnings (Estimated)5/11/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolTSE:MBX CUSIPN/A CIKN/A Webmicrobix.com Phone+1-905-3618910FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio34.00 Forward P/E Ratio38.06 P/E GrowthN/ANet IncomeN/A Net Margins-2.34% Pretax MarginN/A Return on Equity-1.71% Return on Assets0.56% Debt Debt-to-Equity Ratio25.43 Current Ratio6.32 Quick Ratio5.57 Sales & Book Value Annual SalesC$16.72 million Price / Sales3.06 Cash FlowC$0.09 per share Price / Cash Flow4.13 Book ValueC$0.17 per share Price / Book2.18Miscellaneous Outstanding Shares138,450,000Free FloatN/AMarket CapC$51.23 million OptionableNot Optionable Beta0.16 Key ExecutivesMr. Cameron L. GroomePres, CEO & DirectorMr. James S. CurrieChief Financial OfficerDr. Kenneth Hughes Ph.D.Chief Operating OfficerDr. Mark Luscher Ph.D.Sr. VP of Scientific AffairsMr. Philip CasselliSr. VP of Sales, Bus. Devel. & MarketingMr. Christopher B. LobbCompliance Officer, Gen. Counsel & Sec.More ExecutivesKey CompetitorsCeaproCVE:CZOCovalon TechnologiesCVE:COVMedicenna TherapeuticsTSE:MDNAEmerald Health TherapeuticsCVE:EMHProMIS NeurosciencesTSE:PMNView All CompetitorsInsidersPeter Martin BlecherSold 23,500 sharesTotal: C$12,149.50 ($0.52/share)Cameron Lionel GroomeSold 65,000 sharesTotal: C$33,540.00 ($0.52/share)Kenneth HughesBought 11,500 shares on 5/17/2022Total: C$5,347.50 ($0.47/share)View All Insider Transactions MBX Stock - Frequently Asked Questions Should I buy or sell Microbix Biosystems stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Microbix Biosystems in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MBX shares. View MBX analyst ratings or view top-rated stocks. How have MBX shares performed in 2023? Microbix Biosystems' stock was trading at C$0.41 at the start of the year. Since then, MBX stock has decreased by 9.8% and is now trading at C$0.37. View the best growth stocks for 2023 here. When is Microbix Biosystems' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023. View our MBX earnings forecast. How were Microbix Biosystems' earnings last quarter? Microbix Biosystems Inc. (TSE:MBX) announced its quarterly earnings results on Thursday, February, 9th. The company reported ($0.01) EPS for the quarter, hitting analysts' consensus estimates of ($0.01). The business earned $2.50 million during the quarter, compared to the consensus estimate of $2.80 million. Microbix Biosystems had a negative trailing twelve-month return on equity of 1.71% and a negative net margin of 2.34%. What other stocks do shareholders of Microbix Biosystems own? Based on aggregate information from My MarketBeat watchlists, some companies that other Microbix Biosystems investors own include TransAlta Renewables (RNW), Organigram (OGI), Dynavax Technologies (DVAX), Heat Biologics (HTBX), VEON (VEON), Vaxart (VXRT), Wajax (WJX), BlackBerry (BB) and Canadian Western Bank (CWB). What is Microbix Biosystems' stock symbol? Microbix Biosystems trades on the Toronto Stock Exchange (TSX) under the ticker symbol "MBX." How do I buy shares of Microbix Biosystems? Shares of MBX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What is Microbix Biosystems' stock price today? One share of MBX stock can currently be purchased for approximately C$0.37. How much money does Microbix Biosystems make? Microbix Biosystems (TSE:MBX) has a market capitalization of C$51.23 million and generates C$16.72 million in revenue each year. How can I contact Microbix Biosystems? Microbix Biosystems' mailing address is 265 Watline Ave, MISSISSAUGA, ON L4Z 1P3, Canada. The official website for the company is microbix.com. The company can be reached via phone at +1-905-3618910. This page (TSE:MBX) was last updated on 3/24/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.